# EDGAR Filing Document

**Accession Number:** 0000096943
**File Stem:** 0000096943-26-000003
**Filing Date:** 2026-1
**Character Count:** 19821
**Document Hash:** 39b94effab431b3be59e080462563c69
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000096943-26-000003.hdr.sgml**: 20260108

**ACCESSION NUMBER**: 0000096943-26-000003

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260107

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260108

**DATE AS OF CHANGE**: 20260108

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TELEFLEX INC
- **CENTRAL INDEX KEY:** 0000096943
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 231147939
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-05353
- **FILM NUMBER:** 26517321

**BUSINESS ADDRESS:**
- **STREET 1:** 550 E SWEDESFORD RD
- **STREET 2:** SUITE 400
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** 610-225-6800

**MAIL ADDRESS:**
- **STREET 1:** 550 E SWEDESFORD RD
- **STREET 2:** SUITE 400
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087

?xml version='1.0' encoding='ASCII'? tfx-20260107

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K** 

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

---

| | |
|:---|:---|
| **Date of Report (Date of Earliest Event Reported)** | **January 7, 2026** |

---

**TELEFLEX INCORPORATED** 

(Exact name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **<u>Delaware</u>** | **<u>1-5353</u>** | **<u>23-1147939</u>** |
| (State or Other Jurisdiction<br>of Incorporation or Organization) | (Commission File Number) | (IRS Employer<br>Identification No.) |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **<u>550 E. Swedesford Rd., Suite 400</u>** | **<u>Wayne,</u>** | **<u>PA</u>** |  | **<u>19087</u>** |
| **(Address of Principal Executive Offices)** | **(Address of Principal Executive Offices)** | **(Address of Principal Executive Offices)** |  | (Zip Code) |
| Registrant's Telephone Number, Including Area Code |  | **(610)** | **225-6800** |  |

---

---

| |
|:---|
| **Not applicable** |
| **(Former Name or Former Address, If Changed Since Last Report)** |

---

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $1 per share | TFX | New York Stock Exchange |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02. Results of Operations and Financial Condition.** 

On January 8, 2026, Teleflex Incorporated (the "Company") issued a press release announcing certain estimated preliminary financial information for the Company's full year ended December 31, 2025. A copy of the Company's press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 8, 2026, the Company announced the departure of Liam J. Kelly from his roles as the Company's President and Chief Executive Officer, effective as of the end of the day on January 7, 2026 (the "Effective Date"). Furthermore, the Company announced that Stuart A. Randle, a member of the Company's Board of Directors (the "Board"), has been appointed Interim President and Chief Executive Officer, effective as of January 8, 2026 (the "Start Date"). The Board has engaged Spencer Stuart, a leading international executive search firm, to assist with the search for a permanent President and Chief Executive Officer.

Mr. Randle has served on the Board since 2009 and will continue such service during his time as the Company's Interim President and Chief Executive Officer. In connection with Mr. Kelly's departure as President and Chief Executive Officer, the Board appointed Stephen K. Klasko, M.D., the Company's current lead independent director, to serve as the independent Chair of the Board, effective as of the Start Date. In accordance with the terms of Mr. Kelly's existing severance agreement, Mr. Kelly must resign from the Board, and execute a release of claims in favor of the Company and its affiliates, to receive the payments and benefits thereunder.

Mr. Randle, 66, has been a director of the Company since 2009. Mr. Randle retired in December 2018 after serving for three years as the Chief Executive Officer of Ivenix, Inc., a medical device company that provides infusion delivery systems. Previously, Mr. Randle had been retired since September 2014 after serving for ten years as President and Chief Executive Officer of GI Dynamics, Inc., a medical device company. From 2003 to 2004, he served as Interim Chief Executive Officer of Optobionics Corporation, a medical device company. From 2002 to 2003, Mr. Randle held the position of Entrepreneur in Residence of Advanced Technology Ventures, a healthcare and information technology venture capital firm. From 1998 to 2001, he was President and Chief Executive Officer of Act Medical, Inc. Prior to 1998, Mr. Randle held various senior management positions with Allegiance Healthcare Corporation and Baxter International Inc.

Mr. Randle does not have any family relationships with any executive officer or director of the Company. There are no arrangements or understandings with the Company, or any other persons, under which Mr. Randle was elected to serve as an officer of the Company. In addition, he is not party to any transaction requiring disclosure under Item 404(a) of Regulation S-K of the Securities and Exchange Act of 1934, as amended.

*Letter Agreement with Mr. Randle*

In connection with Mr. Randle's appointment, on January 7, 2026, the Company entered into a letter agreement with Mr. Randle pursuant to which Mr. Randle will commence employment effective as of the Start Date and will continue until the date on which a permanent Chief Executive Officer commences employment with the Company (the "Permanent CEO Commencement Date") or, if earlier, Mr. Randle's resignation, termination of his employment by the Company or his death or disability.

The letter agreement provides for the following compensation during Mr. Randle's term of service as Interim President and Chief Executive Officer: a stipend of $140,000 per month (prorated for any partial months of service), a restricted stock grant with a grant date fair value of $1.5 million to be granted on January 13, 2026 (which such award will vest in full on the earlier of the Permanent CEO Commencement Date or the first anniversary of grant, subject to Mr. Randle's continued service through the applicable vesting date) and eligibility to participate in the Company's employee benefit plans.

------

*Separation Benefits for Mr. Kelly*

Mr. Kelly is a party to an existing severance agreement with the Company, dated March 31, 2017 (the "Severance Agreement"). Contingent upon Mr. Kelly's execution of a release of claims in favor of the Company and its affiliates, in connection with his departure, he would receive the severance benefits due upon a termination without cause under the Severance Agreement. Please refer to the description of the post-employment payments and benefits included under the heading "Compensation Discussion and Analysis—Ongoing and Post-Employment Arrangements—Executive Severance Arrangements" in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on March 28, 2025, which description is incorporated herein by reference. Further, Mr. Kelly's outstanding equity awards will receive age and service vesting treatment upon termination to the extent applicable under his existing equity award agreements. Mr. Kelly will be subject to the restrictive covenants included in the Severance Agreement.

The foregoing transition matters were also announced in the Company's press release dated January 8, 2026, which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1&nbsp;&nbsp;&nbsp;&nbsp;<u>[Press Release, dated January 8, 2026](ex991to1-8x20268xkrepressr.htm)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;104&nbsp;&nbsp;&nbsp;&nbsp;The Cover Page from this Current Report on Form 8-K, formatted in Inline XBRL

------

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| Date: January 8, 2026 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TELEFLEX INCORPORATED<br>By: <u>/s/ Daniel V. Logue</u> <br>Name: Daniel V. Logue<br>Title: Corporate Vice President, General Counsel and Secretary |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

## Exhibit 99.1

**Exhibit 99.1**

![imagea.jpg](imagea.jpg)

**Teleflex Announces Leadership Transition**

*Stuart Randle Appointed Interim President and CEO*

*Board Initiates Search for Permanent CEO*

*Dr. Stephen Klasko Appointed Chairman of the Board*

*Company Provides Update on Preliminary Full Year 2025 Revenue Results*

Wayne, Pa., January 8, 2026 – Teleflex Incorporated (NYSE: TFX) today announced that Stuart Randle, a member of the Company's Board of Directors, has been appointed Interim President and Chief Executive Officer, effective immediately. Mr. Randle succeeds Liam Kelly, who departs as Chairman, President and CEO of the Company. Dr. Stephen Klasko, the Company's Lead Director, has been named Chairman of the Board.

The Board has engaged Spencer Stuart, a leading executive search firm, to assist in a comprehensive search process to identify a permanent CEO.

"With the announced sale of our Acute Care, Interventional Urology and OEM businesses, Teleflex is entering its next phase as a more focused, higher-growth organization, as well as executing on the announced transactions and focusing on core critical care and high-acuity hospital markets," said Dr. Klasko. "The Board determined this is the right time to transition leadership and best position the Company for the future. Stuart brings over 35 years of deep medical device leadership and long-standing familiarity with Teleflex as a Board member, and we are confident he will lead effectively during this period."

"I'm pleased to serve as Teleflex's Interim CEO and work alongside the talented leadership team, as well as Steve and the Board, to advance our transformation, drive growth and create value for our stakeholders," said Mr. Randle. "I'm encouraged by the progress we've made, including the recently announced transactions, and see great potential ahead. Our leadership team remains focused on execution and continuity, and I look forward to leading Teleflex during this time of transition."

Dr. Klasko continued, "On behalf of the entire Board, I want to thank Liam for his many contributions to Teleflex over the past 16 years. He has been an important force in driving growth internationally and fostering a purpose-driven company culture focused on excellence, innovation and transparency. We wish him all the best."

------

**Update on Preliminary Full Year 2025 Revenue Results**

Based on information available as of the date of this release, the Company currently expects revenue for the full year 2025 to be $3.270 billion to $3.278 billion as compared to previous guidance of $3.305 billion to $3.320 billion.

The Company noted that the reduction in revenue is principally the result of softer than expected demand for intra-aortic ballon pumps and catheters in the U.S. and Asia at year end and delays in certain purchase orders in the OEM business. Additionally, lower overall order volumes across certain portfolio segments fell short of expectations.

The Company's preliminary full year 2025 revenue results included herein are based on the Company's current estimates and expectations. The Company's financial close process for the quarter is ongoing, and these preliminary results are subject to change and finalization based on customary quarter-end procedures, management review and external audit procedures. The Company cautions investors that if the estimates, expectations or assumptions underlying the preliminary revenue results contained herein prove inaccurate, actual results could differ materially from those expressed in, or implied by, these preliminary revenue results.

The Company expects to report its full fourth quarter and full year 2025 financial results in late February/early March 2026.

**About Stuart Randle**

Mr. Randle has served on the Teleflex Board of Directors since 2009. He brings over 35 years of medical device company experience that has enabled him to provide valuable insights regarding a variety of business, management and technical issues. Mr. Randle retired from Ivenix, Inc. in December 2018, where he served as Chief Executive Officer for three years. Prior to that, he was President and Chief Executive Officer of GI Dynamics for 10 years.

Prior to joining GI Dynamics, Mr. Randle served as Interim Chief Executive Officer of Optobionics Corporation from 2003 to 2004. Prior to that, he held the position of Entrepreneur in Residence of Advanced Technology Ventures from 2002 to 2003 and was President and Chief Executive Officer of Act Medical from 1998 to 2001. Earlier in his career, Mr. Randle held various senior management positions with Allegiance Healthcare Corporation and Baxter International Inc.

**About Teleflex Incorporated** 

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

------

**Forward-Looking Statements** 

Certain statements made in this press release, other than statements of historical fact, are forward-looking statements. These statements include, but are not limited to, statements related to the Company's preliminary full year 2025 revenue results. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "will," "would," "should," "guidance," "potential," "continue," "project," "forecast," "confident," "prospects" and similar expressions typically are used to identify forward-looking statements. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the Company's business and the industry and markets in which the Company operates. These statements are not guarantees of future performance and are subject to risks and uncertainties, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements due to a number of factors, including changes in business relationships with and purchases by or from major customers or suppliers; delays or cancellations in shipments; demand for and market acceptance of new and existing products; the impact of inflation and disruptions in the Company's global supply chain on the Company and its suppliers (particularly sole-source suppliers and providers of sterilization services), including fluctuations in the cost and availability of resins and other raw materials, as well as certain components, used in the production or sterilization of the Company's products, transportation constraints and delays, product shortages, energy shortages or increased energy costs, labor shortages in the United States and elsewhere, and increased operating and labor costs; the Company's inability to effectively execute the announced sale of its Acute Care, Interventional Urology and OEM businesses; the Company's inability to integrate acquired businesses into its operations, realize planned synergies and operate such businesses profitably in accordance with the Company's expectations; the Company's inability to effectively execute its restructuring programs; the Company's inability to realize anticipated savings resulting from restructuring plans and programs; the impact of enacted healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, the implementation or threatened implementation of tariffs, sovereign debt issues, and international conflicts and hostilities, such as the ongoing conflicts between Russia and Ukraine and in the Middle East; public health epidemics and pandemics, such as COVID-19; difficulties entering new markets; and general economic conditions. For a further discussion of the risks relating to the Company's business, see Item 1A, Risk Factors, in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent reports filed with the Securities and Exchange Commission. The Company expressly disclaims any obligation to update these forward-looking statements, except as otherwise explicitly stated by the Company or as required by law or regulation.

**Contacts:** 

Teleflex

Lawrence Keusch

Vice President, Investor Relations and Strategy Development

investor.relations@teleflex.com

610-948-2836

<br>